Literature DB >> 11454184

Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences.

D P Bogdanos1, K Choudhuri, D Vergani.   

Abstract

The pathogenesis of autoimmune liver disease and autoimmunity associated with chronic viral hepatitis remains poorly understood. One of the major hurdles to a deeper understanding of these pathological processes is the absence of clearly defined inductive mechanisms, which, if identified and characterised, could guide clinical strategies for their prevention or allow therapeutic intervention. Molecular mimicry leading to crossreactive autoimmune responses has gained strong experimental support in the past decade. A fundamental premise of this hypothesis is the involvement of a mimicking environmental trigger. In view of the numerous viral and bacterial agents epidemiologically linked to autoimmune liver diseases, we and others have proposed molecular mimicry to be an important mechanism in these diseases. We also propose similar crossreactive mechanisms to operate in the generation of autoimmunity in viral hepatitis. This review focuses on molecular mimicry at the level of the B-cell, as few data on T-cell crossreactivity in liver disease are thus far available.

Entities:  

Mesh:

Year:  2001        PMID: 11454184     DOI: 10.1034/j.1600-0676.2001.021004225.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  43 in total

1.  Identification of beta-subunit of bacterial RNA-polymerase--a non-species-specific bacterial protein--as target of antibodies in primary biliary cirrhosis.

Authors:  Kai-Wolfgang Roesler; Wolfgang Schmider; Manfred Kist; Stephen Batsford; Emile Schiltz; Mathias Oelke; Anja Tuczek; Therese Dettenborn; Dirk Behringer; Wolfgang Kreisel
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

Review 2.  Autoantibodies as prognostic markers in autoimmune liver disease.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-05-13       Impact factor: 3.199

3.  High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?

Authors:  S Berardi; F Lodato; A Gramenzi; A D'Errico; M Lenzi; A Bontadini; M C Morelli; M R Tamè; F Piscaglia; M Biselli; C Sama; G Mazzella; A D Pinna; G Grazi; M Bernardi; P Andreone
Journal:  Gut       Date:  2006-06-23       Impact factor: 23.059

Review 4.  Juvenile autoimmune hepatitis: Spectrum of the disease.

Authors:  Giuseppe Maggiore; Silvia Nastasio; Marco Sciveres
Journal:  World J Hepatol       Date:  2014-07-27

Review 5.  Primary biliary cirrhosis: what do autoantibodies tell us?

Authors:  Chao-Jun Hu; Feng-Chun Zhang; Yong-Zhe Li; Xuan Zhang
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

Review 6.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 7.  Hepatitis C virus infection and type 1 and type 2 diabetes mellitus.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Dilia Giuggioli; Andrea Di Domenicantonio; Ilaria Ruffilli; Alda Corrado; Silvia Fabiani; Santino Marchi; Clodoveo Ferri; Ele Ferrannini; Poupak Fallahi
Journal:  World J Diabetes       Date:  2014-10-15

Review 8.  Cutting edge issues in autoimmune hepatitis.

Authors:  Diego Vergani; Giorgina Mieli-Vergani
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

9.  Chronic intestinal pseudo-obstruction due to lymphocytic intestinal leiomyositis: Case report and literature review.

Authors:  Keiichi Uchida; Kohei Otake; Mikihiro Inoue; Yuhki Koike; Kohei Matsushita; Toshimitsu Araki; Yoshiki Okita; Koji Tanaka; Katsunori Uchida; Noriko Yodoya; Shotaro Iwamoto; Katsuhiro Arai; Masato Kusunoki
Journal:  Intractable Rare Dis Res       Date:  2012-02

Review 10.  Autoantibody-negative autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-12-21       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.